← Leaderboards
John R Hawse
Mayo Clinic Rochester
$6,300,684
Attributed
$7,506,112
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,506,112 · 7
By mechanism
R01$4,415,620 · 2
P50$2,597,846 · 3
R21$443,850 · 1
F32$48,796 · 1
Top collaborators
- Malayannan Subramaniam3 shared
- Thomas C Spelsberg2 shared
- Rajeev Srinivas Muthyala1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Scott H Kaufmann$29,002,745
- Manish Kohli$4,072,306
- Fergus Joseph Couch$34,303,973
- Joanna M Biernacka$6,043,821
- Saravut Weroha$5,625,190
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanIn VitroProteinsSignal TransductionMalignant Breast NeoplasmMortalityResponsePathway InteractionsMediatingBreast Cancer PatientBaseIn VivoDiagnosisTumorBiological MarkersEstradiolErbb2 GeneNeoplasm MetastasisEpidermal Growth Factor ReceptorNeoadjuvant TherapyNew Therapeutic TargetBreast Cancer CellAgonistClinic
Grant awards (22)
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC$488,900
R01 · FY2025 · CA · contact PI
G-Quadruplex-Based Supramolecular Assemblies as Activatable Contrast Agents for In Vitro and In Vivo Fluorescence Imaging of Estrogen Receptor$443,850
R21 · FY2025 · EB · contact PI
Development Research Program$267,960
P50 · FY2025 · CA · contact PI
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC$476,859
R01 · FY2024 · CA · contact PI
Development Research Program$292,913
P50 · FY2024 · CA · contact PI
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC$506,312
R01 · FY2023 · CA · contact PI
Development Research Program$283,457
P50 · FY2023 · CA · contact PI
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC$499,648
R01 · FY2022 · CA · contact PI
Development Research Program$268,093
P50 · FY2022 · CA · contact PI
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC$476,895
R01 · FY2021 · CA · contact PI
Project 2: Therapeutic targeting of estrogen receptor beta in triple negative breast cancer$75,310
P50 · FY2021 · CA · contact PI
Project 2: Therapeutic targeting of estrogen receptor beta in triple negative breast cancer$282,974
P50 · FY2020 · CA · contact PI
Project 2: Therapeutic targeting of estrogen receptor beta in triple negative breast cancer$271,098
P50 · FY2019 · CA · contact PI
Project 2: Therapeutic targeting of estrogen receptor beta in triple negative breast cancer$286,502
P50 · FY2018 · CA · contact PI
Project 2: Therapeutic targeting of estrogen receptor beta in triple negative breast cancer$289,074
P50 · FY2017 · CA · contact PI
Role of a TGF-beta Regulated Gene in Human and Mouse Osteoblasts and Skeleton$393,600
R01 · FY2016 · DE · contact PI
Project 2: Therapeutic targeting of estrogen receptor beta in triple negative breast cancer$280,465
P50 · FY2016 · CA · contact PI
Role of a TGF-beta Regulated Gene in Human and Mouse Osteoblasts and Skeleton$393,600
R01 · FY2015 · DE · contact PI
Role of a TGF-? Regulated Gene in Human and Mouse Osteoblasts and Skeleton$393,600
R01 · FY2014 · DE · contact PI
Role of a TGF-? Regulated Gene in Human and Mouse Osteoblasts and Skeleton$377,856
R01 · FY2013 · DE
Role of a TGF-? Regulated Gene in Human and Mouse Osteoblasts and Skeleton$408,350
R01 · FY2012 · DE
Role of sex steroids in female TIEG-null mouse bone loss$48,796
F32 · FY2006 · AR · contact PI